PHOENIX, May 17, 2019 (GLOBE NEWSWIRE) -- Item 9
Labs Corp. (INLB) (âItem 9 Labsâ or
the âCompanyâ), a leader in comfortable cannabis health solutions
for the modern consumer, today announced earnings for the second
quarter which ended March 31, 2019.
Item 9 Labs Corp and its subsidiaries made great
strides in operations in the three and six months ended March 31,
2019. Operating efficiency has increased dramatically which can be
seen in the growth in margins over the same periods in fiscal 2018.
The expansion of the Arizona facility (completed in March 2019)
should prove to increase the efficiency and revenues beginning in
Overview for the three months ended
March 31, 2019 as compared to the three months ended March 31,
Overview for the six months ended March
31, 2019 as compared to the six months ended March 31,
For information visit Item9LabsCorp.com.
About Item 9 Labs
Corp.:Item 9 Labs Corp. (INLB) creates comfortable cannabis health solutions
for the modern consumer. The Company is bringing best of industry
practices to markets from coast to coast through cultivation and
production, distinctive retail environments, licensing services,
and diverse product suites catering to different medical cannabis
demographics. Item 9 Labs Corp. is headquartered in Phoenix,
Arizona, with medical cannabis operations in multiple U.S.
Item 9 Labs Corp.âs asset portfolio includes
Dispensary Permits, Dispensary Templates, and Strive Life. These
assets provide services specific to different stakeholder groups.
Dispensary Permits is the Companyâs consulting firm specializing in
strategic license application and compliance. Dispensary Templates,
a subdivision of the firm, is a technology platform with an
extensive digital library of licensing and business planning
resources. Strive Life is a turnkey dispensary model for the retail
sector, elevating the patient experience with consistent and
superior service, high-end design, and precision-tested products.
It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the
industry with its dynamic product suites. The Company has created
complementary brands Item 9 Labs and Strive Wellness to channel
consumer diversity. Proprietary delivery platforms include the
Apollo Vape and Pod system, as well as a pioneering intra-nasal
device. The Company has received multiple accolades for its
medical-grade flower and concentrates.
Item 9 Labs Corp. will be managing cultivation,
processing, distribution, and dispensary operations in up to ten
U.S. markets by the end of 2019. Current facilities include
distribution and processing operations Strive Wellness of Ohio and
Strive Wellness of Nevada, as well as dispensary Strive Life North
For more information, visit Item 9 Labs Corp.
Statement: This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements involve risks and uncertainties, including, but not
limited to, risks and effects of legal and administrative
proceedings and governmental regulation, especially in a foreign
country, future financial and operational results, competition,
general economic conditions, proposed transactions that are not
legally binding obligations of the company and the ability to
manage and continue growth. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual outcomes may vary materially from those
indicated. Important factors that could cause actual results to
differ materially from the forward-looking statements we make in
this news release include the introduction of new technology,
market conditions and those set forth in reports or documents we
file from time to time with the SEC. We undertake no obligation to
revise or update such statements to reflect current events or
circumstances after the date hereof or to reflect the occurrence of
Item 9 Labs Corp.